The impact of the clinical trial of venetoclax (ABT-199) and obinutuzumab in CLL

Thomas Kipps, MD from the University of California, San Diego, CA, discussed the impact of the clinical trial of venetoclax (ABT-199) with obinutuzumab in the treatment landscape chronic lymphocytic leukemia (CLL).

Share this video